echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Rational Design and Tuning of Ribozyme-Based Devices

    Rational Design and Tuning of Ribozyme-Based Devices

    • Last Update: 2021-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A synthetic gene-regulatory device platform was described by modularly assembling three RNA components encoding distinct functions of sensing, transmission, and actuation. The molecular binding at the sensor component is translated by the transmitter component through a strand-displacement event to modulate activity of the actuator component, which then interacts with cellular transcriptional machinery to affect gene expression levels. Here, we provide some general guidelines on linking RNA components to construct gene-regulatory devices and strategies to tune device regulatory activities through an RNA folding �program for specific cellular applications.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.